0.180
0.01 (5.23%)
| Penutupan Terdahulu | 0.171 |
| Buka | 0.171 |
| Jumlah Dagangan | 40,158 |
| Purata Dagangan (3B) | 1,209,312 |
| Modal Pasaran | 852,424 |
| Harga / Jualan (P/S) | 0.100 |
| Harga / Buku (P/B) | 0.100 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Mar 2026 |
| Margin Operasi (TTM) | -255.98% |
| EPS Cair (TTM) | -2.23 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -39.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 92.65% |
| Nisbah Semasa (MRQ) | 1.03 |
| Aliran Tunai Operasi (OCF TTM) | -15.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 5.61 M |
| Pulangan Atas Aset (ROA TTM) | -30.92% |
| Pulangan Atas Ekuiti (ROE TTM) | -162.30% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | ProPhase Labs, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 7.99% |
| % Dimiliki oleh Institusi | 11.64% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Sykon Capital Llc | 31 Dec 2025 | 64,478 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Feb 2026 | Pengumuman | ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative |
| 02 Feb 2026 | Pengumuman | Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd |
| 26 Jan 2026 | Pengumuman | ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture |
| 22 Jan 2026 | Pengumuman | ProPhase Labs Uplists from Pink Sheets to OTC Market |
| 05 Jan 2026 | Pengumuman | ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value |
| Purata Hasil Dividen 5T | 0.21% |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 24 May 2022 | 09 May 2022 | 03 Jun 2022 | 0.3 Tunai |
| 28 Feb 2022 | 14 Feb 2022 | 10 Mar 2022 | 0.3 Tunai |
| 24 May 2021 | 12 May 2021 | 03 Jun 2021 | 0.3 Tunai |
| 02 Dec 2019 | 20 Nov 2019 | 12 Dec 2019 | 0.25 Tunai |
| 09 Jan 2019 | 24 Dec 2018 | 24 Jan 2019 | 0.25 Tunai |
| 06 Jun 2018 | 07 May 2018 | 05 Jun 2018 | 1 Tunai |
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2022 | 0.600 | 2 | 0.62 |
| 2021 | 0.300 | 1 | 0.42 |
| 2019 | 0.500 | 2 | 2.54 |
| 2018 | 1.00 | 1 | 3.18 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |